Global Blood Therapeutics, Inc. Form SC 13G/A February 13, 2018

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)*

Global Blood Therapeutics, Inc.

(Name of Issuer)

COMMON STOCK, \$0.001 PAR VALUE PER SHARE

(Title of Class of Securities)


37890U108

(CUSIP Number)

December 31, 2017

(Date of Event Which Requires Filing of this Statement)

Edgar Filing: Global Blood Therapeutics, Inc. - Form SC 13G/A



Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)

The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

^{*} The remainder of this cover page shall be filled out for a reporting person s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

CUSIP No. 37890U108			8 SCHEDULE 13G	Page 2 of 15 Pages
1.	NAME	S OF	REPORTING PERSONS	
2.			Ventures II, L.P. E APPROPRIATE BOX IF A MEMBER OF A GROUP	
	(a)	(b		
3.	SEC U	SE O	NLY	
4.	CITIZE	ENSH	IP OR PLACE OF ORGANIZATION	
	Delawa	are 5.	SOLE VOTING POWER	
NUME	BER OF			
	ARES ICIALLY	6.	0 SHARED VOTING POWER	
OWN	ED BY	7.	0 SOLE DISPOSITIVE POWER	
PER	RTING RSON ITH	8.	0 SHARED DISPOSITIVE POWER	
9.	AGGR	EGA'	0 ГЕ AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PER	RSON
10.	0 CHECI	к во	X IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTA	IN SHARES

0.0%(1)

12. TYPE OF REPORTING PERSON

PN

(1) The percent of class was calculated based on 46,007,393 shares of common stock issued and outstanding as of December 19, 2017, as disclosed in the Issuer s Prospectus Supplement filed with the Securities and Exchange Commission on December 19, 2017.

CUSIP No. 37890U10	8 SCHEDULE 13G	Page 3 of 15 Pages
1. NAMES OF	REPORTING PERSONS	
	Ventures GP II, L.P. E APPROPRIATE BOX IF A MEMBER OF A GRO	OUP
(a) (b)	
3. SEC USE O	NLY	
4. CITIZENSI	IIP OR PLACE OF ORGANIZATION	
Delaware 5.	SOLE VOTING POWER	
NUMBER OF		
SHARES 6. BENEFICIALLY	0 SHARED VOTING POWER	
OWNED BY EACH 7.	0 SOLE DISPOSITIVE POWER	
REPORTING PERSON 8. WITH	0 SHARED DISPOSITIVE POWER	
9. AGGREGA	0 TE AMOUNT BENEFICIALLY OWNED BY EAC	H REPORTING PERSON
0 10. CHECK BC	X IF THE AGGREGATE AMOUNT IN ROW (9) E	XCLUDES CERTAIN SHARES

0.0% (1)

12. TYPE OF REPORTING PERSON

PN

CUSIP No. 37890U108			8 SCHEDULE 13G	Page 4 of 15 Pages
1.	NAME	S OF	REPORTING PERSONS	
2.	TRV G		LLC E APPROPRIATE BOX IF A MEMBER OF A GROUP	
	(a)	(b		
3.	SEC U	SE O	NLY	
4.	CITIZE	ENSE	IIP OR PLACE OF ORGANIZATION	
	Delawa	are 5.	SOLE VOTING POWER	
NUME	BER OF			
	ARES	6.	0 SHARED VOTING POWER	
	CIALLY			
	ED BY CH	7.	0 SOLE DISPOSITIVE POWER	
REPO!	RTING			
	SON ITH	8.	0 SHARED DISPOSITIVE POWER	
9.		EGA	0 TE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERS	SON
10.	0 CHECI	К ВО	X IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN	N SHARES

0.0% (1)

12. TYPE OF REPORTING PERSON

OO

CUSIP No. 37890U108			8 SCHEDULE 13G	Page 5 of 15 Pages
1.	NAME	ES OF	REPORTING PERSONS	
2.			Ventures III, L.P. E APPROPRIATE BOX IF A MEMBER OF A GROUP	
	(a)	(t		
3.	SEC U	SE O	NLY	
4.	CITIZI	ENSF	IIP OR PLACE OF ORGANIZATION	
	Delawa	are 5.	SOLE VOTING POWER	
NUMB	BER OF			
	RES	6.	0 SHARED VOTING POWER	
BENEFI				
	ED BY	7.	0 SOLE DISPOSITIVE POWER	
	.CH	, .	SOLL DISTOSITIVE TO WER	
	RTING SON	8.	0 SHARED DISPOSITIVE POWER	
WI	TH			
9.	AGGR	EGA	0 TE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERS	SON
10.	0 CHEC	К ВС	X IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN	N SHARES

0.0% (1)

12. TYPE OF REPORTING PERSON

PN

CUSIP I	No. 37890U10	8 SCHEDULE 13G	Page 6 of 15 Pages
1.	NAMES OF	REPORTING PERSONS	
2.		E Ventures GP III, L.P. E APPROPRIATE BOX IF A MEMBER OF A GROUP	
	(a) (l))	
3.	SEC USE C	NLY	
4.	CITIZENSI	HIP OR PLACE OF ORGANIZATION	
	Delaware 5.	SOLE VOTING POWER	
NUMB	BER OF		
SHA BENEFI	ARES 6.	0 SHARED VOTING POWER	
	ED BY CH 7.	0 SOLE DISPOSITIVE POWER	
PER	RTING SON 8.	0 SHARED DISPOSITIVE POWER	
9.	AGGREGA	0 TE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING P	PERSON
10.	0 CHECK BO	X IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERT	ΓAIN SHARES

0.0% (1)

12. TYPE OF REPORTING PERSON

PN

CUSIP No.	. 37890	U10	8 SCHEDULE 13G	Page 7 of 15 Pages
1. N	NAMES	S OF	REPORTING PERSONS	
	TRV G		, LLC E APPROPRIATE BOX IF A MEMBER OF A GROUP	
(8	a)	(b)	
3. S	SEC US	E O	NLY	
4. C	CITIZE	NSH	IP OR PLACE OF ORGANIZATION	
Γ	Delawai	re 5.	SOLE VOTING POWER	
NUMBER	R OF			
SHARE BENEFICIA		6.	0 SHARED VOTING POWER	
OWNED EACH	BY	7.	0 SOLE DISPOSITIVE POWER	
REPORTI PERSO WITH	Ν	8.	0 SHARED DISPOSITIVE POWER	
9. A	AGGRE	EGA'	0 ГЕ AMOUNT BENEFICIALLY OWNED BY EACH REPORTING F	PERSON
10. C		ВО	X IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERT	TAIN SHARES

0.0% (1)

12. TYPE OF REPORTING PERSON

OO

CUSIP N	No. 3789	0U10	SCHEDULE 13G	Page 8 of 15 Pages			
1.	NAMES OF REPORTING PERSONS						
2.	Mark Levin CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) (b)						
3.	SEC U	SE O	NLY				
4.	CITIZI	ENSF	HIP OR PLACE OF ORGANIZATION				
	United	State 5.	SOLE VOTING POWER				
NUMB SHA BENEFIC	RES	6.	301,507 SHARED VOTING POWER				
	ED BY CH	7.	0 SOLE DISPOSITIVE POWER				
PER	RTING SON TH	8.	301,507 SHARED DISPOSITIVE POWER				
9.	AGGR	EGA	0 TE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSO	ON			
10.	301,50° CHEC		X IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN	SHARES			

0.7% (1)

12. TYPE OF REPORTING PERSON

IN

CUSIP No. 37890U108)U10	8 SCHEDULE 13G	Page 9 of 15 Pages		
1.	NAMES OF REPORTING PERSONS					
2.	Kevin P. Starr CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) (b)					
3.	SEC US	SE O	NLY			
4.	CITIZE	NSH	IIP OR PLACE OF ORGANIZATION			
	United S	State 5.	SOLE VOTING POWER			
NUMB SHA BENEFIC	RES	6.	151,847 SHARED VOTING POWER			
	ED BY CH	7.	0 SOLE DISPOSITIVE POWER			
PER	RTING SON TH	8.	151,847 SHARED DISPOSITIVE POWER			
9.	AGGRE	EGA'	0 ГЕ AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSO	ON		
10.	151,847 CHECK		X IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN	SHARES		

0.3% (1)

12. TYPE OF REPORTING PERSON

IN

CUSIP No. 37890U108 **SCHEDULE 13G** Page 10 of 15 Pages 1. NAMES OF REPORTING PERSONS Robert I. Tepper CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP 2. (a) (b) 3. SEC USE ONLY CITIZENSHIP OR PLACE OF ORGANIZATION 4. **United States** 5. **SOLE VOTING POWER** NUMBER OF 291,957 **SHARES** 6. SHARED VOTING POWER **BENEFICIALLY OWNED BY** 0 SOLE DISPOSITIVE POWER 7. **EACH REPORTING** 291,957 **PERSON** 8. SHARED DISPOSITIVE POWER **WITH** 0 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 291,957 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

0.6% (1)

12. TYPE OF REPORTING PERSON

IN

CUSIP No. 37890U108 SCHEDULE 13G Page 11 of 15 Pages

Item 1. Issuer

(a) Name of Issuer:

Global Blood Therapeutics, Inc. (the **Issuer**)

(b) Address of Issuer s Principal Executive Offices:

400 East Jamie Court

South San Francisco, CA 94080

Item 2. Filing Person

- (a) (c) Name of Persons Filing; Address; Citizenship:
 - (i) Third Rock Ventures II, L.P. (**TRV II**);
 - (ii) Third Rock Ventures GP II, L.P. (**TRV GP II**), which is the sole general partner of TRV II;
 - (iii) TRV GP II, LLC (TRV GP II LLC), which is the sole general partner of TRV GP II;
 - (iv) Third Rock Ventures III, L.P. (**TRV III**);
 - (v) Third Rock Ventures GP III, L.P. (**TRV GP III**), which is the sole general partner of TRV III;
 - (vi) TRV GP III, LLC (TRV GP III LLC), which is the sole general partner of TRV GP III;
 - (vii) Mark Levin (Levin), a managing member of TRV GP II LLC and TRV GP III LLC;
 - (viii) Kevin P. Starr (**Starr**), a managing member of TRV GP II LLC and TRV GP III LLC; and
 - (ix) Robert I. Tepper (**Tepper**, and collectively with TRV II, TRV GP II, TRV GP II LLC, TRV III, TRV GP III, TRV GP III LLC, Levin and Starr, the **Reporting Persons**), a managing member of TRV GP II LLC and TRV GP III LLC.

The address of the principal business office of each of the Reporting Persons is Third Rock Ventures, LLC, 29 Newbury Street, 3rd Floor, Boston, MA 02116.

Each of TRV II, TRV III, TRV GP II and TRV GP III is a Delaware limited partnership. Each of TRV GP II LLC and TRV GP III LLC is a Delaware limited liability company. Levin, Tepper and Starr are United States citizens.

(d) Title of Class of Securities:

Common stock, \$0.001 par value per share, (the **Common Stock**)

(e) CUSIP Number:

37890U108

Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

Edgar Filing: Global Blood Therapeutics, Inc. - Form SC 13G/A

(a)	Broker or dealer registered under Section 15 of the Act;
(b)	Bank as defined in Section 3(a)(6) of the Act;
(c)	Insurance company as defined in Section 3(a)(19) of the Act;
(d)	Investment company registered under Section 8 of the Investment Company Act of 1940;
(e)	An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

CUSIP No. 37890U108 SCHEDULE 13G Page 12 of 15 Pages

- (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
- (j) A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
- (k) Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

Item 4. Ownership.

- (a) and (b) Amount beneficially owned:
 - (i) TRV II directly owns 0 shares of Common Stock.
 - (ii) TRV GP II is the general partner of TRV II and directly owns 0 shares of Common Stock.
 - (iii) TRV GP II LLC is the general partner of TRV GP II and directly owns 0 shares of Common Stock.
 - (iv) TRV III directly owns 0 shares of Common Stock.
 - (v) TRV GP III is the general partner of TRV III and directly owns 0 shares of Common Stock.
 - (vi) TRV GP III LLC is the general partner of TRV GP III and directly owns 0 shares of Common Stock.
 - (vii) Levin is a managing member of TRV GP II LLC and TRV GP III LLC. As of December 31, 2017, Levin directly owns 301,507 shares of Common Stock, which represents 0.7% of the outstanding shares of Common Stock.
 - (viii) Starr is a managing member of TRV GP II LLC and TRV GP III LLC. As of December 31, 2017, Starr directly owns 151,847 shares of Common Stock, which represents 0.3% of the outstanding shares of Common Stock.
 - (ix) Tepper is a managing member of TRV GP II LLC and TRV GP III LLC. As of December 31, 2017, Tepper directly owns 291,957 shares of Common Stock, which represents 0.6% of the outstanding shares of Common Stock.
 - (c) Number of shares as to which such person has:

	Number	Number of Shares of Common Stock				
Reporting Person	(i)	(ii)	(iii)	(iv)		
TRV II	0	0	0	0		
TRV GP II	0	0	0	0		

Edgar Filing: Global Blood Therapeutics, Inc. - Form SC 13G/A

TRV GP II LLC	0	0	0	0
TRV III	0	0	0	0
TRV GP III	0	0	0	0
TRV GP III LLC	0	0	0	0
Levin	301,507	0	301,507	0
Starr	151,847	0	151,847	0
Tepper	291,957	0	291,957	0

- (i) Sole power to vote or direct the vote
- (ii) Shared power to vote or to direct the vote
- (iii) Sole power to dispose or to direct the disposition of
- (iv) Shared power to dispose or to direct the disposition of

CUSIP No. 37890U108

SCHEDULE 13G

Page 13 of 15 Pages

The percent of class was calculated based on 46,007,393 shares of common stock issued and outstanding as of

December 19, 2017, as disclosed in the Issuer s Prospectus Supplement filed with the Securities and Exchange

Commission on December 19, 2017.

Item 5. Ownership of Five Percent or Less of a Class.

Not applicable.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent

Holding Company or Control Person.

Not applicable.

Item 8. Identification and Classification of Members of the Group.

Not applicable.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certification.

Not applicable.

CUSIP No. 37890U108 SCHEDULE 13G Page 14 of 15 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 13, 2018

THIRD ROCK VENTURES II, L.P.

By: THIRD ROCK VENTURES GP II, L.P., General Partner

By: TRV GP II, LLC, General Partner

By: /s/ Kevin Gillis Kevin Gillis Chief Financial Officer

THIRD ROCK VENTURES GP II, L.P.

By: TRV GP II, LLC, General Partner

By: /s/ Kevin Gillis Kevin Gillis Chief Financial Officer

TRV GP II, LLC

By: /s/ Kevin Gillis Kevin Gillis Chief Financial Officer

THIRD ROCK VENTURES III, L.P.

By: THIRD ROCK VENTURES GP III, L.P., General Partner

By: TRV GP III, LLC, General Partner

By: /s/ Kevin Gillis Kevin Gillis Chief Financial Officer CUSIP No. 37890U108 SCHEDULE 13G Page 15 of 15 Pages

THIRD ROCK VENTURES GP III, L.P.

By: TRV GP III, LLC, General Partner

By: /s/ Kevin Gillis Kevin Gillis Chief Financial Officer

TRV GP III, LLC

By: /s/ Kevin Gillis Kevin Gillis Chief Financial Officer

MARK LEVIN

/s/ Kevin Gillis, As attorney-in-fact Mark Levin

KEVIN P. STARR

/s/ Kevin Gillis, As attorney-in-fact Kevin P. Starr

ROBERT I. TEPPER

/s/ Kevin Gillis, As attorney-in-fact Robert I. Tepper

EXHIBIT 24

POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Kevin Gillis his true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in his capacity as a direct or indirect general partner, director, officer, member or manager of any partnership, corporation or limited liability company, pursuant to section 13 or 16 of the Securities Exchange Act of 1934, as amended (the Exchange Act), and any and all regulations promulgated thereunder, and to file the same, with all exhibits thereto, and any other documents in connection therewith, with the Securities and Exchange Commission, and with any other entity when and if such is mandated by the Exchange Act or by the Financial Industry Regulatory Authority, granting unto said attorney-in-fact full power and authority to do and perform each and every act and thing necessary, desirable or appropriate, fully to all intents and purposes as he might or could do in person, thereby ratifying and confirming all that said attorney-in-fact, or his substitutes, may lawfully do or cause to be done by virtue hereof. Each of the undersigned may execute this power of attorney in separate counterparts, and each counterpart shall be deemed to be an original instrument. This agreement shall be effective as to each of the undersigned as of the date signed by that signatory.

IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 16th day of January, 2014.

/s/ Mark Levin Mark Levin

/s/ Kevin P. Starr Kevin P. Starr

/s/ Robert I. Tepper Robert I. Tepper

EXHIBIT 99.1

Joint Filing Agreement

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained herein, but shall not be responsible for the completeness and accuracy of the information concerning the other entities or persons, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate.

Date: February 13, 2018

THIRD ROCK VENTURES II, L.P.

By: THIRD ROCK VENTURES GP II, L.P., General Partner

By: TRV GP II, LLC, General Partner

By: /s/ Kevin Gillis Kevin Gillis Chief Financial Officer

THIRD ROCK VENTURES GP II, L.P.

By: TRV GP II, LLC, General Partner

By: /s/ Kevin Gillis Kevin Gillis Chief Financial Officer

TRV GP II, LLC

By: /s/ Kevin Gillis Kevin Gillis Chief Financial Officer

THIRD ROCK VENTURES III, L.P.

By: THIRD ROCK VENTURES GP III, L.P., General Partner

By: TRV GP III, LLC, General Partner

By: /s/ Kevin Gillis Kevin Gillis Chief Financial Officer

THIRD ROCK VENTURES GP III, L.P.

By: TRV GP III, LLC, General Partner

By: /s/ Kevin Gillis Kevin Gillis Chief Financial Officer

TRV GP III, LLC

By: /s/ Kevin Gillis Kevin Gillis Chief Financial Officer

MARK LEVIN

/s/ Kevin Gillis, As attorney-in-fact Mark Levin

KEVIN P. STARR

/s/ Kevin Gillis, As attorney-in-fact Kevin P. Starr

ROBERT I. TEPPER

/s/ Kevin Gillis, As attorney-in-fact Robert I. Tepper